Joseph L. Leach

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.8K citations · Full text

Medicine, Genetics, Oncology +14

Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

Michael J. Overman, Scott Kopetz, Joseph L. Leach et al. · Journal of Clinical Oncology · 2016 · 139 citations

Pharmacy, Oncology, Pharmacotherapy +17

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.

James L. Gulley, David R. Spigel, Karen Kelly et al. · Journal of Clinical Oncology · 2015 · 94 citations

Medicine, Oncology, Pharmacology +17

Endoscopic Resection of the Intranasal Frontal Sinus Floor

Lanny Garth Close, Joseph L. Leach, Norris K. Lee et al. · Annals of Otology Rhinology & Laryngology · 1994 · 93 citations

Medicine, Otolaryngology, Surgery +9

Comparison of Microtia Reconstruction Outcomes Using Rib Cartilage vs Porous Polyethylene Implant

Kristin K. Constantine, Jim Gilmore, Kenneth Lee et al. · JAMA Facial Plastic Surgery · 2014 · 83 citations

Medicine, Orthopedic Surgery, Bone Grafting +5